Anthony Manning
13Patents
3h-index
24Co-inventors
60Inventor score
Filing activity: Feb 18, 1997 → May 9, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5932425A | Compositions and methods for modulating cellular NF-.kappa.B activation | Human Necessities | 11 | Expired |
| US7119114B1 | Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto | Chemistry; Metallurgy | 10 | Expired |
| US6656713B2 | Compounds and methods for modulating activation of NF-&kgr;B | Human Necessities | 5 | Expired |
| US10464996B2 | Methods for the treatment of neurodegeneration | Emerging Cross-Sectional Technologies | 3 | Active |
| US10676526B2 | FcRn antibodies and methods of use thereof | Chemistry; Metallurgy | 3 | Active |
| US7414120B2 | Compounds and methods for modulating activation of NF-κB | Human Necessities | 1 | Active |
| US11345751B2 | FcRn antibodies and methods of use thereof | Chemistry; Metallurgy | 1 | Active |
| US11352415B2 | Methods for the treatment of neurodegeneration | Emerging Cross-Sectional Technologies | 1 | Active |
| US7186503B2 | Compounds and methods for modulating activation of NF-κB | Human Necessities | 1 | Expired |
| US8263326B2 | Compounds and methods for modulating activation of NF-κB | Human Necessities | 0 | Active |
| US7335676B2 | Methods for treating inflammatory conditions or inhibiting JNK | Chemistry; Metallurgy | 0 | Expired |
| US12297256B2 | Methods for the treatment of neurodegeneration | Emerging Cross-Sectional Technologies | 0 | Active |
| US11732047B2 | FcRn antibodies and methods of use thereof | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.